Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease

被引:30
作者
Alonso, R
Suarez, A
Castro, P
Lacave, AJ
Gutierrez, C
机构
[1] Univ Oviedo, Dept Funct Biol, Area Immunol, Oviedo, Spain
[2] Univ Oviedo, IUOPA, Oviedo, Spain
[3] Hosp Univ Cent Asturias, Dept Immunol, Oviedo, Spain
[4] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain
关键词
gender; genetic polymorphism; interleukin-10; malignant melanoma; overall survival; recurrence;
D O I
10.1097/00008390-200502000-00009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Individual ability to produce interleukin-10 (IL-10) may be of relevance in the development and evolution of cutaneous melanoma, probably due to its immunosuppressor and anti-angiogenic properties. Single nucleotide polymorphisms at positions - 1082 (G/A), - 819 (C/T) and - 592 (C/A) in the IL-10 gene promoter were analysed in 100 healthy individuals and 98 melanoma patients using fluorogenic hybridization-specific probes in a 'real-time' thermocycler. Polymorphic frequencies were correlated with various prognostic factors and overall survival. The frequency of IL-10 polymorphic variants was similar in patients and controls. However, high producer genotypes at the - 1082 position were over-represented in males with an older age at diagnosis. The analysis of the promoter genotypes in patients stratified according to clinical prognostic factors did not show any associations, although a trend (not statistically significant) towards a prolonged survival in patients genotyped as high IL-10 producers was observed. In addition, the low producer - 1082AA genotype was significantly associated with decreased survival in patients with advanced disease. Similarly, the presence of this genotype shortened the overall survival in males after recurrence or metastasis development. In conclusion, the frequency of genetic variants in the IL-10 gene promoter was not associated with melanoma appearance, but conditioned the age at diagnosis in males and the overall survival in patients with advanced disease. (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:53 / 60
页数:8
相关论文
共 43 条
[1]   Testosterone and estrogen differently effect TH1 and TH2 cytokine release following trauma-haemorrhage [J].
Angele, MK ;
Knöferl, MW ;
Ayala, A ;
Bland, KI ;
Chaudry, IH .
CYTOKINE, 2001, 16 (01) :22-30
[2]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[3]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[4]  
Berman RM, 1996, J IMMUNOL, V157, P231
[5]   Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma [J].
Boyano, MD ;
Garcia-Vázquez, MD ;
López-Michelena, T ;
Gardeazabal, J ;
Bilbao, J ;
Cañavate, ML ;
De Galdeano, AG ;
Izu, R ;
Díaz-Ramón, L ;
Raton, JA ;
Díaz-Pérez, JL .
BRITISH JOURNAL OF CANCER, 2000, 83 (07) :847-852
[6]   Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the TL10 promoter-592 C/C genotype [J].
Breen, EC ;
Boscardin, WJ ;
Detels, R ;
Jacobson, LP ;
Smith, MW ;
O'Brien, SJ ;
Chmiel, JS ;
Rinaldo, CR ;
Lai, SH ;
Martínez-Maza, O .
CLINICAL IMMUNOLOGY, 2003, 109 (02) :119-129
[7]   Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10 [J].
Cervenak, L ;
Morbidelli, L ;
Donati, D ;
Donnini, S ;
Kambayashi, T ;
Wilson, JL ;
Axelson, H ;
Castaños-Velez, E ;
Ljunggren, HG ;
Malefyt, RD ;
Granger, HJ ;
Ziche, M ;
Bejarano, MT .
BLOOD, 2000, 96 (07) :2568-2573
[8]   PRODUCTION OF IL-10 BY MELANOMA-CELLS - EXAMINATION OF ITS ROLE IN IMMUNOSUPPRESSION MEDIATED BY MELANOMA [J].
CHEN, QY ;
DANIEL, V ;
MAHER, DW ;
HERSEY, P .
INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (05) :755-760
[9]   Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma [J].
Cunningham, LM ;
Chapman, C ;
Dunstan, R ;
Bell, MC ;
Joske, DJL .
LEUKEMIA & LYMPHOMA, 2003, 44 (02) :251-255
[10]   ELEVATED SERUM LEVELS OF INTERLEUKIN-10 IN PATIENTS WITH METASTATIC MALIGNANT-MELANOMA [J].
DUMMER, W ;
BECKER, JC ;
SCHWAAF, A ;
LEVERKUS, M ;
MOLL, T ;
BROCKER, EB .
MELANOMA RESEARCH, 1995, 5 (01) :67-68